%PDF-1.4
%
63 0 obj
<>
endobj
60 0 obj
<>
endobj
126 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-29T12:42:35Z
2024-03-28T12:52:41-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T12:52:41-07:00
application/pdf
Heather
201206.aug
uuid:a9acd595-1dd1-11b2-0a00-d609278d5b00
uuid:a9acd598-1dd1-11b2-0a00-1e0000000000
endstream
endobj
49 0 obj
<>
endobj
50 0 obj
<>
endobj
64 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
36 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
39 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
42 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
160 0 obj
[164 0 R]
endobj
161 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:8)Tj
0 Tw -46.2952 -0.0313 Td
(1922)Tj
ET
0 0 0 0 scn
/GS0 gs
102.63 58.38 407.5 -10.83 re
f*
0.5 w
102.63 58.38 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
8 0 0 8 74.4 714.5293 Tm
(1998;16:125-34.)Tj
0.02499 Tw -2.175 -1.25 Td
[(34.)-875 (Koczan D, Ringel B, Kohler H, et al. Splicing of Fas receptor)]TJ
2.175 -1.25 Td
(molecules \(CD95\) in children having juvenile chronic arthritis)Tj
0 -1.25 TD
[([abstract]. Rev Rhum Engl Ed 1997;64 Suppl:21)36.9 (1S.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875.1 (Prieur )54.8 (AM, Roux-Lombard P)110.7 (, Dayer J. Dynamics of fever and)]TJ
0 Tc 2.175 -1.25 Td
(cytokine network in systemic juvenile arthritis. Rev Rhum Engl Ed)Tj
0 Tw T*
(1996;63:171-7.)Tj
0.0249 Tw -2.175 -1.25 Td
[(36.)-875 (Kr\366emer G. )17.7 (The proto-oncogene Bcl-2 and its role in regulating)]TJ
2.175 -1.25 Td
(apoptosis. Nature Med 1997;3:614-20.)Tj
-2.175 -1.25 Td
[(37.)-875 (Schirmer M, )17.7 (V)111.1 (allejo )54.8 (A, )17.7 (W)79.8 (eyand CM, Goronzy J. Resistance to)]TJ
2.175 -1.25 Td
(apoptosis and elevated expression of Bcl-2 in clonally expanded)Tj
T*
[(CD4+CD28- )17.8 (T)-257.2 (cells from rheumatoid arthritis patients. J Immunol)]TJ
0 Tw T*
(1998;161:1018-25.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(38.)-875.1 (Firestein GS, )36.8 (Y)100 (eo M, Zvaifler N. )54.8 (Apoptosis in rheumatoid arthritis)]TJ
0 Tc 2.175 -1.25 Td
(synovium. J Clin Invest 1995;96:1631-8.)Tj
0.0072 Tw -2.175 -1.25 Td
[(39.)-875 (Sugiyama )-17.8 (M, T)69.8 (sukazaki T)74 (, )19.1 (Y)100.1 (onekura )37.1 (A, )-17.7 (Matsuzaki )-17.7 (S, )19.1 (Y)100.1 (a)0.1 (mashita )-17.8 (S,)]TJ
-0.00011 Tc 0.02499 Tw 2.175 -1.25 Td
(Iwasaki K. Localization of apoptosis and expression of apoptosis-)Tj
0 Tc T*
(related proteins in the synovium of patients with rheumatoid)Tj
T*
[(arthritis. )54.9 (Ann Rheum Dis 1996;55:442-9.)]TJ
-2.175 -1.25 Td
[(40.)-875 (Murray K, Luyrink L, Grom )54.8 (A, et al. Immunohistological)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(characteristics of )17.7 (T)-257.3 (cell infiltrates in dif)17.7 (ferent forms of childhood)]TJ
0 Tc T*
[(onset chronic arthritis. J Rheumatol 1996;23:21)36.9 (16-24.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(41.)-875.1 (Burmester G, Stuhlmuller B, Keyszer G, Kinne R. Mononuclear)]TJ
0 Tc 2.175 -1.25 Td
(phagocytes and rheumatoid synovitis: Mastermind or workhorse in)Tj
T*
(arthritis? J Rheumatol 1997;40:5-18.)Tj
-2.175 -1.25 Td
[(42.)-875 (T)69.8 (ak P)110.8 (,)0.1 ( Smeets )17.7 (T)74 (, Daha M, et al. )54.8 (Analysis of the synovial cell)]TJ
2.175 -1.25 Td
(infiltrate in early rheumatoid synovial tissue in relation to local)Tj
T*
[(disease activity)64.9 (. )54.9 (Arthritis Rheum 1997;40:217-25.)]TJ
-2.175 -1.25 Td
[(43.)-875 (Akbar )54.8 (A, Borthwick N, )17.7 (W)39.8 (ickremasinge R, et al. Interleukin-2)]TJ
2.175 -1.25 Td
(receptor common gamma-chain signaling cytokines regulate)Tj
-0.00011 Tc T*
[(activated )17.7 (T)-257.3 (cell apoptosis in response to growth factor withdrawal:)]TJ
0 Tc T*
(selective induction of anti-apoptotic \(bcl-2, bcl-xL\) but not pro-)Tj
T*
(apoptotic \(bax, bcl-xS\) expression. Eur J Immunol 1996;26:294-9.)Tj
-0.00011 Tc 30.825 40 Td
[(44.)-875.1 (Salmon M, Scheel-T)69.7 (oellner D, Huissoon )54.8 (A, et al. Inhibition of )17.7 (T)]TJ
0 Tc 2.175 -1.25 Td
(cell apoptosis in the rheumatoid synovium. J Clin Invest)Tj
0 Tw T*
(1997;99:439-46.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(45.)-875.1 (Murray K, Grom )54.8 (A, )17.7 (Thompson S, Lieuwen D, Passo M, Glass D.)]TJ
0 Tc 2.175 -1.25 Td
[(Contrasting cytokine profiles in the synovium of dif)17.8 (ferent forms of)]TJ
T*
(juvenile rheumatoid arthritis and juvenile spondyloarthropathy:)Tj
T*
(Prominence of interleukin-4 in restricted disease. J Rheumatol)Tj
0 Tw T*
(1998;25:1388-98.)Tj
0.0249 Tw -2.175 -1.25 Td
[(46.)-875 (Blasser C, Kaufmann M, Muller C, et al. Beta-galactosidase-)]TJ
2.175 -1.25 Td
[(binding protein secreted by activated )17.8 (T)-257.2 (cells inhibits antigen-)]TJ
T*
[(induced proliferation of )17.8 (T)-257.2 (cells. Eur J Immunol 1998;28:231)36.9 (1-9.)]TJ
-2.175 -1.25 Td
[(47.)-875 (Adams L, Kenneth G, )17.7 (W)79.8 (einber)17.8 (g C. Biphasic modulation of cell)]TJ
2.175 -1.25 Td
[(growth by recombinant human galectin-1. Biochim Biophys )54.9 (Acta)]TJ
0 Tw T*
(1996;1312:137-44.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(48.)-875.1 (Rabinovich GA, Modesti NM, Castagna LF)79.7 (, Landa CA, Riera CM,)]TJ
0 Tc 2.175 -1.25 Td
(Sotomayor CE. Specific inhibition of lymphocyte proliferation and)Tj
T*
(induction of apoptosis by CLL-1, a beta-galactoside-binding lectin.)Tj
T*
(J Biochem 1997;122:365-73.)Tj
-2.175 -1.25 Td
[(49.)-875 (Bresalier R, Mazurek N, Stember)17.8 (g L, et al. Metastasis of human)]TJ
2.175 -1.25 Td
(colon cancer is altered by modifying expression of the beta-)Tj
T*
(galactoside-binding protein galectin-3. Gastroenterology)Tj
0 Tw T*
[(1998;1)36.9 (15:287-96.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(50.)-875.1 (Barondes S, Cooper D, Gitt M, Lef)17.7 (fler H. Galectins: Structure and)]TJ
0 Tc 2.175 -1.25 Td
[(function of a lar)17.8 (ge family of animal lectins. J Biol Chem)]TJ
0 Tw T*
(1994;269:20807-10.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(51.)-875.1 (Cyster JG, Fowell D, Barclay )54.8 (AN. )54.8 (Antigen determinants encoded)]TJ
0 Tc 2.175 -1.25 Td
(by alternatively spliced exons of CD45 are determined by the)Tj
T*
(polypeptide but influenced by glycosylation. Int Immunol)Tj
0 Tw T*
(1994;6:1875-81.)Tj
0.0249 Tw -2.175 -1.25 Td
[(52.)-875 (V)111.1 (espa GN, Lewis LA, Kozak KR, et al. Galectin-1 specifically)]TJ
2.175 -1.25 Td
[(modulates )17.8 (TCR signal to enhance )17.8 (TCR apoptosis but inhibit IL-2)]TJ
T*
(production and proliferation. J Immunol 1999;162:799-806.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
107 0 obj
<>
endobj
131 0 obj
<>
endobj
68 0 obj
<>
endobj
72 0 obj
<>
endobj
71 0 obj
<>
endobj
99 0 obj
<>stream
HtV
pT}ow$$ >A!,a7@#I` %#?*LhH@։hP";)[`p҂bݗ
f|{~sٷ;VAÔ9ON:<iR : Εz~k =e^KJ ~ɼyG*smZ[ZDk?/./0&n,zhxq;(7s=/X%aMZgzO+kViK@ˀQ"Mۊ^uA\j--d`/c#/
"ڇhї0a6ul?~bةUY̠6Ӹ8*NX}frQhNU%8AbpuIx;xlqtfbD8!^1zY&y濈nf-Cλ!UCSuJ7@"_Lz
X9݄p]}K$T,$d9>ѪIC?wތ][V/b13
0Q
9{>@C+{8s(sRq\J)e?9P]6yJkZ
j[][
B/9r*bucGbkjc6^ft&کv,1x:#8[ni1JsX٢TEX.Vbi:I8)N3:[.&
9@e1i6),eD.QlͲEiaiSYOGccc39Y |